Starting Dose of Rosuvastatin: 10 mg vs 20 mg
Start rosuvastatin at 10 mg daily for most patients, as this is the FDA-approved usual starting dose that achieves LDL-C reductions of 46-48% and allows 80% of patients to reach NCEP ATP III goals. 1
FDA-Approved Starting Dose
The recommended starting dose is 10 mg once daily for the majority of adult patients with hyperlipidemia, taken at any time of day with or without food. 1
Rosuvastatin 10 mg reduces LDL-C by approximately 46.7-48.1%, which is significantly more effective than atorvastatin 10 mg (36.4%), simvastatin 20 mg (35.7%), or pravastatin 20 mg (27.1%). 1, 2
Approximately 80% of patients achieve their NCEP ATP III LDL-C goals with rosuvastatin 10 mg, compared to only 53% with atorvastatin 10 mg. 1, 3
When to Start at Lower Doses (5 mg)
Initiate at 5 mg daily in these specific populations:
Asian patients due to increased rosuvastatin plasma concentrations (approximately 2-fold higher AUC). 1
Severe renal impairment (CrCl <30 mL/min/1.73 m² not on hemodialysis); do not exceed 10 mg daily in this population. 1
Patients on cyclosporine, tacrolimus, everolimus, or sirolimus: limit dose to 5 mg daily due to severe drug-drug interactions that increase statin exposure and muscle toxicity risk. 4, 1
Patients on darolutamide: do not exceed 5 mg daily. 1
When to Consider Starting at 20 mg
Starting at 20 mg may be appropriate for:
Patients with very high baseline LDL-C (>190 mg/dL) who require aggressive initial therapy, though most guidelines still recommend starting at 10 mg and titrating up after 4 weeks if needed. 1
Homozygous familial hypercholesterolemia (HoFH): the recommended dose is 20 mg daily in both adults and pediatric patients ≥7 years. 1
Heterozygous familial hypercholesterolemia (HeFH) in patients ≥10 years old: can use up to 20 mg daily (5-10 mg for ages 8-10 years). 1
Evidence Supporting 10 mg as Starting Dose
Rosuvastatin 10 mg achieves 82% goal attainment for NCEP ATP III targets, which increases to 89% with 40 mg. 2
Each dose escalation provides incremental but diminishing LDL-C reductions: 10 mg vs 5 mg reduces LDL-C by an additional 6.25 percentage points; 20 mg vs 10 mg adds 5.84 percentage points; 40 mg vs 20 mg adds only 5.03 percentage points. 5
A recent trial showed that rosuvastatin 10 mg plus ezetimibe 10 mg was superior to rosuvastatin 20 mg monotherapy for achieving LDL-C <1.4 mmol/L (69.2% vs 44.2%, p<0.01), suggesting that combination therapy at lower statin doses may be preferable to dose escalation. 6
Safety Considerations
Tolerability is generally consistent across the 5-40 mg dose range, with the exception that proteinuria risk is significantly higher with 40 mg vs 20 mg (p=0.01). 5
Myopathy and rhabdomyolysis risk increases with higher doses, particularly in patients with risk factors (age >80 years, renal impairment, polypharmacy, concomitant fibrates). 1
Assess LDL-C as early as 4 weeks after initiation and adjust dosage if necessary rather than starting at a higher dose. 1
Common Pitfalls to Avoid
Do not start at 40 mg: this is not a recommended starting dose and carries higher risk of adverse effects without proportional benefit. 1, 5
Do not overlook drug interactions: many immunosuppressants, antivirals, and other medications require dose limitations (see Table 1 in FDA label). 4, 1
Do not forget to wait 2 hours before aluminum/magnesium antacids if the patient takes these medications. 1
Do not assume all statins are equivalent: rosuvastatin 10 mg is significantly more potent than equivalent doses of other statins. 1, 2, 7